The FDA approved Vanda Pharmaceuticals’ oral drug Nereus (tradipitant) for preventing vomiting due to motion sickness. The agency’s decision is based on three pivotal studies, including two phase III real‑world trials conducted at sea and an additional supportive trial. Vanda plans a commercial launch in the coming months and reported a sharp intraday stock reaction after the approval. Nereus is a neurokinin‑1 receptor antagonist aimed at an indication that has seen little drug development for decades. The approval provides clinicians a new pharmacologic option for motion‑induced emesis and gives Vanda a near‑term commercial product to support revenues and pipeline investments.